Newly developed dual topoisomerase inhibitor P8-D6 is highly active in ovarian cancer

BACKGROUND: Ovarian cancer (OvCa) constitutes a rare and highly aggressive malignancy and is one of the most lethal of all gynaecologic neoplasms. Due to chemotherapy resistance and treatment limitations because of side effects, OvCa is still not sufficiently treatable. Hence, new drugs for OvCa the...

Descripción completa

Detalles Bibliográficos
Autores principales: Flörkemeier, Inken, Steinhauer, Tamara N., Hedemann, Nina, Ölander, Magnus, Artursson, Per, Clement, Bernd, Bauerschlag, Dirk O.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: SAGE Publications 2021
Materias:
Original Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8649464/
https://www.ncbi.nlm.nih.gov/pubmed/34887943
http://dx.doi.org/10.1177/17588359211059896

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8649464/
https://www.ncbi.nlm.nih.gov/pubmed/34887943
http://dx.doi.org/10.1177/17588359211059896

Ejemplares similares